open/close global search bar

01 January 2015

Atlas image

Photograph of a patient from Cerro de Pasco (4300 m) with Chronic Mountain Sickness

AI00156.jpg
Richalet J-P,Rivera M,Maignan M,Pham I,Privat C,Leon-Velarde F.Pulmonary hypertension and monges disease. [Internet]. 2009 ;1:114. Available from:http://www.pvrireview.org/text.asp?2009/1/2/114/50730

Photograph of a patient from Cerro de Pasco (4300 m) with Chronic Mountain Sickness, presenting cyanosis of the lips and a typical color of the face.

 

Additional keywords: patient,chronic mountain sickness,cerro de pasco

Related Content

Adaptation to high-altitude living thumbnail image

Conference talk

27 January 2014

{{GlobalController.truncateTitle("Adaptation to high-altitude living", 65)}}
Cardiac output and maximal tricuspid regurgitation pressure (as an index of systolic pulmonary artery pressure) in three groups of subjects thumbnail image

Atlas image

01 January 2015

{{GlobalController.truncateTitle("Cardiac output and maximal tricuspid regurgitation pressure (as an index of systolic pulmonary artery pressure) in three groups of subjects", 65)}}
Relationship between pulmonary artery pressure and arterial oxygen saturation in CMS patients and healthy highlanders thumbnail image

Atlas image

01 January 2015

{{GlobalController.truncateTitle("Relationship between pulmonary artery pressure and arterial oxygen saturation in CMS patients and healthy highlanders", 65)}}
Variation of serum erythropoietin ( EPO, a), soluble transferrin receptors ( sTfR, b) and ferritin ( Ferritin, c) thumbnail image

Atlas image

01 January 2015

{{GlobalController.truncateTitle("Variation of serum erythropoietin ( EPO, a), soluble transferrin receptors ( sTfR, b) and ferritin ( Ferritin, c)", 65)}}
Effect of 3- and 6-month treatment with either acetazolamide (ACZ) or placebo on pulmonary vascular resistance and pulmonary acceleration time in CMS patients thumbnail image

Atlas image

01 January 2015

{{GlobalController.truncateTitle("Effect of 3- and 6-month treatment with either acetazolamide (ACZ) or placebo on pulmonary vascular resistance and pulmonary acceleration time in CMS patients", 65)}}

Add to reading list

Please enter a list name.

Our research platform is the world.

Through worldwide collaboration, we can begin to answer the question of a global disease.

Join the PVRI
standard-example-image.jpg